- Home
- COEP vs PULM Comparison
COEP vs PULM Comparison
Compare COEP & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- PULM
- Stock Information
- Founded
- COEP 2017
- PULM 2003
- Country
- COEP United States
- PULM United States
- Employees
- COEP N/A
- PULM N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- PULM Health Care
- Exchange
- COEP Nasdaq
- PULM Nasdaq
- Market Cap
- COEP 27.4M
- PULM 33.2M
- IPO Year
- COEP N/A
- PULM N/A
- Fundamental
- Price
- COEP $9.47
- PULM $6.38
- Analyst Decision
- COEP
- PULM
- Analyst Count
- COEP 0
- PULM 0
- Target Price
- COEP N/A
- PULM N/A
- AVG Volume (30 Days)
- COEP 37.4K
- PULM 59.3K
- Earning Date
- COEP 08-15-2025
- PULM 08-12-2025
- Dividend Yield
- COEP N/A
- PULM N/A
- EPS Growth
- COEP N/A
- PULM N/A
- EPS
- COEP N/A
- PULM N/A
- Revenue
- COEP $62,874.00
- PULM $1,921,000.00
- Revenue This Year
- COEP N/A
- PULM N/A
- Revenue Next Year
- COEP N/A
- PULM $134.88
- P/E Ratio
- COEP N/A
- PULM N/A
- Revenue Growth
- COEP N/A
- PULM N/A
- 52 Week Low
- COEP $2.31
- PULM $1.78
- 52 Week High
- COEP $13.70
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- COEP 62.24
- PULM 39.53
- Support Level
- COEP $7.25
- PULM $6.26
- Resistance Level
- COEP $9.90
- PULM $6.96
- Average True Range (ATR)
- COEP 0.63
- PULM 0.85
- MACD
- COEP 0.26
- PULM -0.11
- Stochastic Oscillator
- COEP 85.62
- PULM 39.71
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).